Weight Loss

What to Look for in a Protein Powder?

Besides a balanced diet, many individuals opt to include supplements as part of their daily food intake. Protein powder is one such supplement which has become increasingly popular over recent years, with many users who want to achieve weight loss and muscle growth.

Semaglutide and Weight Loss in Menopause

Cachexia / Wasting Syndrome

What Is Cancer Cachexia? Causes, Symptoms, Diagnosis, and Treatment

Who Should Take Weight Loss Injections, and Who Shouldn’t?

The Natural Molecule That Could Rival Ozempic

Is a Hypocaloric Diet Safe and Effective for Long-Term Health?

Vegetarian Diets for Weight Loss

Military Diet: Health Risks

Oral GLP-1 Pills for Weight Loss: How Orforglipron Works

Mental Health Disorders, Weight Gain, and Exercise

Cachexia and Cancer

See more featured articles »

GLP-1 and Diet: Evidence-Based Strategies for Better Weight Loss

Circadian Rhythm and Weight Loss

Wegovy: A Breakthrough in Weight Loss?

How Oral GLP-1 Drugs Work For Weight Loss

Weight Loss After Bariatric Surgery

How Does Semaglutide Work to Lose Weight?

Is Cottage Cheese Good for Weight Loss? Evidence from Clinical Studies

Unexplained Weight Loss: When It Might Signal a Health Problem

What's Next for Semaglutide? Beyond Diabetes and Weight Loss

Does Cinnamon Help with Weight Loss?

Latest Weight Loss News and Research

To avoid care disruptions, know when the clock runs out on your prior authorization

A woman with multiple sclerosis wanted to be able to walk up the stairs at home without losing her balance.

27 Feb 2026

Targeting glutamine metabolism offers new hope for synovial sarcoma treatment

Synovial sarcoma is an aggressive malignant tumor that primarily affects the limbs of teenagers and young adults.

26 Feb 2026

Untreated sleep apnea may cost the UK and US billions annually

Untreated obstructive sleep apnea may be costing the UK and US economies billions of pounds/dollars in lost productivity every year, with a considerable proportion of working age adults experiencing symptoms indicative of the breathing disorder, suggests an analysis published online in the journal Thorax.

24 Feb 2026

Combined GLP-1 and GLP-2 treatment appears safe but does not beat placebo for obesity

In a 12-week randomized phase IIa trial in adults with obesity, the dual GLP-1/GLP-2 receptor agonist dapiglutide was well tolerated but did not achieve statistically significant weight loss compared with placebo at 4 mg or 6 mg doses. Although the higher dose showed modest within-group weight reduction and improved HbA1c, unexpectedly substantial placebo-associated weight loss limited the observed treatment effect.

24 Feb 2026

Tirzepatide activates brown fat, boosting metabolism beyond appetite control

Tirzepatide is one of the drugs that has revolutionized the treatment of obesity and other conditions such as diabetes in recent years.

24 Feb 2026

Transforming obese fat cells into energy burners

Ordinary fat cells in obese animals can be induced to burn energy stores, generating substantial heat, according to a preclinical study by Weill Cornell Medicine investigators.

23 Feb 2026

Higher ultra-processed food intake aligns with greater binge eating risk in obesity study

Higher intake of ultra-processed foods in adults with obesity was associated with disordered eating symptoms, poorer diet quality, and lower protein intake. The cross-sectional findings suggest dietary processing level may influence eating behaviour patterns relevant to obesity management, though causality cannot be inferred.

23 Feb 2026

Gut microbiome may shape response to GLP-1 drugs, new review suggests

This review examines how GLP-1 receptor agonists and the gut microbiome influence one another through bile acid signaling, short-chain fatty acids, and inflammatory pathways. It explores how microbial composition may shape treatment response and highlights the need for controlled human studies to enable microbiome-informed precision therapy.

19 Feb 2026

Intermittent calorie restriction proves as effective as daily calorie cuts for type 2 diabetes

A post-hoc analysis of two clinical trials compared continuous calorie restriction with early time-restricted eating in adults with type 2 diabetes and overweight or obesity over three months. Both approaches improved weight, body composition, and metabolic health, with no clear superiority except for lower dropout with intermittent restriction.

18 Feb 2026

How GLP-1 drugs affect the body beyond weight loss and glucose control

This review evaluates the safety profile of glucagon-like peptide-1 receptor agonists and related incretin therapies used for obesity and type 2 diabetes. It highlights common gastrointestinal effects, rare but debated risks, and areas where further long-term safety data are still needed.

18 Feb 2026

Oral weight loss ingredient may have adverse biological effects for the gut and beyond

A new study from Adelaide University is turning a spotlight on those tablet versions, finding that the absorption-enhancing ingredient salcaprozate sodium (SNAC) may have measurable adverse biological effects for the gut and beyond.

17 Feb 2026

Does intermittent fasting help you lose more weight? Evidence review finds no clear advantage

A Cochrane systematic review of 22 randomized trials involving 1,995 adults with overweight or obesity found intermittent fasting produces weight loss comparable to traditional calorie restriction. Evidence suggests little additional benefit for quality of life or adverse effects, with overall certainty ranging from low to moderate and long-term effects still unclear.

17 Feb 2026

Intermittent fasting does not seem to work for overweight or obese adults

Intermittent fasting is unlikely to lead to greater weight loss in overweight or obese adults than traditional dietary advice or doing nothing, a new Cochrane review finds.

16 Feb 2026

Big breakfast study reveals protein curbs appetite but fiber delivers stronger gut microbiome benefits

A randomized crossover weight loss trial in adults with overweight or obesity found that higher protein big breakfasts improved satiety, while higher fibre breakfasts produced slightly greater weight loss and more favourable gut microbiota markers. Both diets improved metabolic biomarkers, but microbiota changes reflected surrogate gut health indicators rather than direct clinical outcomes.

15 Feb 2026

Obesity sharply increases hospitalisation risk from infections, global analysis shows

Adult obesity is associated with a substantially higher risk of severe hospital-treated or fatal infections across multiple pathogens, with risk increasing as obesity severity rises. Global modelling suggests roughly one in ten infection-related deaths worldwide may be attributable to adult obesity, although causality cannot be confirmed.

15 Feb 2026

AI tool predicts optimal feeding tube timing for people with MND

A new AI tool that accurately predicts the need for a feeding tube could transform patient care and improve quality of life for people living with Motor Neurone Disease (MND).

13 Feb 2026

Parkinson's-related weight loss reflects a failure of the body's energy-producing pathways

Weight loss is a well-recognized but poorly understood non-motor feature of Parkinson's disease (PD). Many patients progressively lose weight as the disease advances, often alongside worsening motor symptoms and quality of life.

13 Feb 2026

Ozempic users continue treatment when weight loss works despite side effects

A study on Ozempic for weight loss reveals user satisfaction is driven by efficacy, despite common gastrointestinal side effects impacting treatment adherence.

13 Feb 2026

Weight loss drug tirzepatide may lower the risk of diabetic retinopathy

The popular diabetes and weight loss medication tirzepatide (brand name Mounjaro or Zepbound) may lower the risk of diabetic retinopathy, a leading cause of vision loss, according to Weill Cornell Medicine investigators.

11 Feb 2026

Semaglutide lowers cardiovascular events even without major weight loss, researchers report

Semaglutide reduced major adverse cardiovascular events in adults with overweight or obesity and established cardiovascular disease regardless of baseline adiposity. Cardiovascular benefit was largely independent of overall weight loss, with waist circumference reduction explaining only part of the effect.

11 Feb 2026